Health Condition 1: null- Allergic keratoconjunctivitis Health Condition 2: H162- Keratoconjunctivitis
Conditions
Interventions
Intervention1: Chloroquine phosphate: It is the phosphate salt of chloroquine, a quinoline compound with antimalarial and anti-inflammatory properties.
route of administration- topical (ocular)
dose
Sponsors
FDC Limited
Eligibility
Inclusion criteria
Inclusion criteria: All patients coming in the outpatient department with ocular itching, redness and watering and diagnosed as a case of seasonal allergic conjunctivitis on the basis of sign (hyperemia and papillaae) at slit lamp examination.
Exclusion criteria
Exclusion criteria: 1. Uveitis, conjunctivitis (due to other cause) and other ocular pathology. 2. Bronchial asthma, eczema. 3. History of dry eye, blepharitis, using contact lens. 4. Receiving topical or systemic medication. 5. History of hypersensitivity to any constituents of the eye drops.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptom control Timepoint: follow up 1week, 4 week, 8 week and 12 week. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. decrease in tear osmolarity 2. decrease in Inflammtory markers MMP9 Alpha antitrypsin, Interleukin1, interleukin 8, interferon gamma levelTimepoint: before treatment and at last follow up | — |
Countries
India
Contacts
Public ContactNamrata Sharma
Dr.R.P.Centre for Ophthalmic Sciences, AIIMS
Outcome results
None listed